Vasopeptidase inhibition: A new concept in blood pressure management

Journal of Hypertension, Supplement

Volumn 17, Issue 1, 1999, Pages

  Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiotensin converting enzyme; Natriuretic peptides; Neutral endopeptidase; Vasopeptidase inhibitors

Indexed keywords

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; OMAPATRILAT; UNCLASSIFIED DRUG; VASOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; CONFERENCE PAPER; DRUG EFFICACY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HALF LIFE TIME; HEART FAILURE; HEART MUSCLE CELL; HEART PERFORMANCE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL; VASOCONSTRICTION; VASODILATATION;

AMINO ACID SEQUENCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; HUMANS; HYPERTENSION; MOLECULAR SEQUENCE DATA; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; PYRIDINES; THIAZEPINES;

EID: 0033011038     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:2413-2446.
2. American Heart Association. Valvular heart disease. 1998 Heart and Stroke: Statistical Update. Dallas: American Heart Association; 1997. p 18.
3. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339:1957-1963.
4. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115-1118.
5. Robl JA, Trippodo NC, Petrillo EW. Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme. In: van Zwieten PA, Greenlee WJ (editors): Antihypertensive Drugs. Australia: Harwood Academic Publishers; 1997. pp. 113-211.
6. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990; 15:S20-S24.
7. Packer M. Drugs for heart failure that interfere with the renin - angiotensin system. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS (editors): Heart Failure: Scientific Principles and Clinical Practice. New York: Churchill Livingstone; 1997, pp. 687-690.
8. th edition. Philadelphia: WB Saunders Company; 1997, pp. 855-856.
9. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339:1285-1292.
10. Chen HH, Burnett JC Jr. C-type natriuretic peptide. The endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998; 32 (suppl 3):S22-S28.
11. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238:675-678.
12. Grantham JA, Burnett, JC Jr. Natriuretic peptides in cardiovascular disease. In: Samson WK, Levin ER (editors): Contemporary Endocrinology. Natriuretic Peptides in Health and Disease. Humana Press Inc.: Totowa, NJ; 1997, pp. 309-326.
13. Boland DG, Abraham WT. Natriuretic peptides in heart failure. CHF March/April 1998. pp. 23-33.
14. Stein BC, Levin RI. Natriuretic peptides. Physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998; 135:914-923.
15. Wilkins MR, Redondo J, Brown LA. The natriuretic peptide family. Lancet 1997;349:1307-1310.
16. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25:227-234.
17. Oliver PM, John SW, Purdy KE, Kim R, Maeda N, Goy MF, et al. Natriuretic peptide receptor I expression influences blood pressures of mice in a dose-dependent manner. Proc Natl Acad Sci USA 1998; 95:2547-2551.
18. Yang HYT, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970; 214:374-376.
19. th edition. Baltimore: Williams & Wilkins; 1998, pp. 181-249.
20. Gibbons GH. Cardioprotective mechanisms of ACE inhibition. The angiolensin II-nitric oxide balance. Drugs 1997; 54 (suppl 5):1-11.
21. th edition. Philadelphia: WB Saunders Company; 1997, pp. 471-491.
22. Schiffrin EL. Vascular protection with newer antihypertensive agents. J Hypertens 1998; 16 (suppl 5):S25-S29.
23. Susic D, Frohlich ED. Nephroprotoctive effect of antihyportensive drugs in essential hypertension. J Hypertens 1998; 16:555-567.
24. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992; 262:H308-H312.
25. Margulies KB, Barclay PL, Burnett JC Jr. The role of neutral endopeptidasc in dogs with evolving congestive heart failure. Circulation 1995; 91:2036-2042.
26. Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3:145-151.
27. Fink CA. Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Exp Opin Ther Patients 1996; 6:1147-1164.
28. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC Jr. Neutral ondopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 1998; 275:F410-F414.
29. Trippodo NC, Gabel RA, Harvey CM, Asaad MM, Rogers WL. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J Cardiovasc Pharmacol 1991; 18:308-316.
30. Sybertz EJ. Drugs inhibiting the metabolism and inactivation of atrial natriuretic factor. Pharmacological actions and therapeutic implications. Cardio Drug Rev 1990; 8:71-82.
31. Di lorio R, Marinoni E, Letizia C, Alo P, Villaccio B, Cosmi EV. Adrenomedullin, a new vasoactive peptide, is increased in preeclampsia. Hypertension 1998; 32:758-763.
32. Munzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992; 86:1089-1098.
33. Chen HH, Schirger JA, Chau WL, Lisy O, Redfield MM, Jougasaki M, et al. The renal response to acute neutral endopeptidase inhibition is determined by the severity of heart failure [abstract 527]. Circulation 1998; 98 (suppl 1): I-104.
34. Haneda M, Kikkawa R, Maeda S, Togawa M, Koya D, Hoide N, et al. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int 1991; 40:188-194.
35. Smith JB, Lincoln TM. Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor. Am J Physiol 1987; 253:C147-C150.
36. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101:812-818.
37. Supaporn T, Wennberg PW, Wei CM, Kinoshita M, Matsuda Y, Burnett JC Jr. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin Sci 1996; 90:357-362.
38. Yamamoto K, Burnett JC Jr., Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997; 273:H2406-H2414.
39. Margulies KB, Perrella MA, McKinley LJ, Burnett, JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991; 88:1636-1642.
40. Robl JA, Sun CO, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, et al. Dual metalloprotease inhibitors. Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997; 40:1570-1577.
41. French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol 1995; 26:107-113.
42. Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995; 275:745-752.
43. Vera WG, Fournié-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JP, et al. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther 1995; 272:343-351.
44. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR, et al. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 11:363-372.
45. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad M. Simultaneous inhibition of neutral endopeplidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition [abstract]. Circulation 1998; 98:I-781.
46. Thomas CV, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Hebbar L, et al. Dual metalloprotease inhibition during the development of left ventricular failure; effects on left ventricular myocyte beta-adrenergic response [abstract]. Circulation 1997; 98:1-520.
47. Thomas C, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Hebbar L, et al. Dual metalloprotease inhibition during the development of left ventricular failure: effects on left ventricular and myocyte function and geometry [abstract 2935]. Circulation 1997; 98:1-524.
48. Vestorqvist O, Liao W, Manning JA, Uderman H, Delaney C, Beierle F, et al. Effects of BMS-1867, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) activity in healthy men [abstract PIV-46]. Clin Pharmacol Ther 1997; 61:230.
49. Liao W, Delaney C, Smith R, Lubin S, McNulty S, Davis K, et al. Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) in healthy male subjects [abstract PIV-45]. Clin Pharmacol Ther 1997; 61:229.